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ABSTRACT The objective of this study was to explore the following aspects of tei-
coplanin use in patients with hematological malignancy: early attainment of target
trough concentrations with current high-dose teicoplanin regimens, variability in un-
bound teicoplanin fractions, factors associated with observed total and unbound
trough concentrations, efﬁcacy and toxicity, and renal function estimation. This was
a single-center, prospective study. Samples for determination of trough concentra-
tions were taken on days 3, 4, 7, and 10. Total and unbound teicoplanin concentra-
tions were determined using validated high-performance liquid chromatography
methods. Regression analyses were used to identify the factors associated with the
trough concentration. Thirty teicoplanin-treated adults with hematological malig-
nancy were recruited. Despite the use of dosages higher than the conventional dos-
ages, the proportions of patients with a trough concentration of 20 mg/liter at 48
h and at 72 h were 16.7% and 37.9%, respectively. Renal function was signiﬁcantly
negatively associated with total trough concentrations at 48 h and 72 h (P  0.05).
For an average hematological malignancy patient (creatinine clearance  70 ml/
min), sequential loading doses of at least 12 mg/kg of body weight may be needed
to achieve early adequate exposure. In the absence of measured creatinine clear-
ance, estimates obtained using the Cockcroft-Gault (total body weight) equation
could prove to be an acceptable surrogate. The unbound fractions of teicoplanin
were highly variable (3.4 to 18.8%). Higher unbound fractions were observed in pa-
tients with low serum albumin concentrations. Teicoplanin was well tolerated. Teico-
planin loading doses higher than those in current use appear to be necessary. In-
creased dosing is needed in patients with increased renal function. The high
variability in protein binding supports the contention for therapeutic drug monitor-
ing of unbound teicoplanin concentrations. (This study has been registered with
EudraCT under registration no. 2013-004535-72.)
KEYWORDS teicoplanin, hematological malignancy, therapeutic drug monitoring,
pharmacokinetics, protein binding
Infection is one of the most common complications of chemotherapy-induced neu-tropenia (1). Hematological malignancy patients are at greater risk for severe neu-
tropenia than solid tumor patients because of the underlying disease as well as the
severely myelosuppressive chemotherapy used for treatment (2). The increasing inci-
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dence of Gram-positive pathogens in these patients is well recognized, and as these
pathogens are often methicillin resistant, glycopeptide antibiotics, commonly, teico-
planin or vancomycin, have an important role in their treatment (1). Teicoplanin is
considered a useful alternative to vancomycin: it is as effective as vancomycin, can be
administered once daily, and is associated with fewer side effects (3). Indeed, surveys
conducted in the UK and Ireland have found teicoplanin commonly to be the preferred
choice for patients with hematological malignancy (4, 5). However, the emergence of
teicoplanin resistance is a signiﬁcant concern (6–8) and, coupled with the impaired
ability of neutropenic patients to ﬁght infection, makes it important to achieve ade-
quate exposure rapidly (9).
The ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/
MIC) is thought to be the pharmacokinetic/pharmacodynamic index best correlating
with glycopeptide efﬁcacy (10–12). However, calculation of the AUC requires multiple
samples, and therefore trough concentrations are used as a surrogate marker to assess
exposure in daily clinical practice (13). While the summary of product characteristics for
teicoplanin speciﬁes a target trough concentration of 10 mg/liter for most infections
(14), a higher trough target has been advocated for hematological malignancy patients
(15, 16). Indeed, the trough target for teicoplanin in hematological malignancy patients
recommended at Tallaght Hospital is 20 mg/liter, with higher-than-conventional
doses being speciﬁed to achieve this.
As teicoplanin is highly protein bound (90 to 95%) (17), altered serum albumin
concentrations may have variable effects on total and unbound concentrations (18).
Knowledge of unbound concentrations may be more relevant than knowledge of total
concentrations to predict the outcome, as unbound concentrations are responsible for
antimicrobial activity and correlate best with drug response (18). Previous data have
suggested that albumin concentrations play a major role in the variability of the
unbound fraction (free fraction [FF]) of teicoplanin (13, 19–21). Altered FFs of teicopla-
nin and a lack of correlation between unbound and total concentrations might also be
expected in hematological malignancy patients, in whom low albumin concentrations
are common (22).
We previously reported a mixed-effects regression model explaining 52% of the
variability in trough total teicoplanin concentrations in hematological malignancy
patients and identiﬁed dose, day of therapy, renal function, and a diagnosis of acute
myeloid leukemia (AML) to be signiﬁcant factors associated with trough total concen-
trations (16). However, due to the retrospective nature of that study, critical character-
istics that might also affect trough concentrations were not available, including ﬂuid
balance, illness severity measures, and measured creatinine clearance (CLCR). Further-
more, there was a lack of consistency in both dosing and the day of trough concen-
tration measurements.
The objectives of this study were (i) to assess whether current high-dose regimens
of teicoplanin result in attainment of the target trough concentration on days 3 and 4,
(ii) to determine the variability in the FF of teicoplanin, (iii) to identify factors associated
with both the total and unbound trough concentrations attained on days 3 and 4, (iv)
to describe efﬁcacy and toxicity, and (v) to compare the performance of renal function
estimation equations for estimation of the measured CLCR.
RESULTS
Thirty patients were recruited into the study. A summary of the demographic and
clinical characteristics of the included patients is provided in Table 1. Coagulase-
negative staphylococcal (CoNS) central line-associated bloodstream infection (CLABSI)
was the most common microbiologically documented infection occurring in the cohort
(n  7, 33.3%). Three patients (10%) died during their admission, and death was
attributed to progression of the malignancy in all cases.
Dosing regimens. All 30 patients received three initial loading doses ranging from
330 mg to 800 mg (4.7 to 13.8 mg/kg of body weight). Twenty-nine patients received
maintenance doses of 600 mg or 800 mg (7.3 and 13.8 mg/kg/day, respectively) once
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daily. One patient received 800 mg (8.8 mg/kg) once daily up to day 8 and then twice
daily thereafter. The duration of teicoplanin therapy ranged from 3 to 20 days.
Trough concentrations. High interpatient variability in trough total and unbound
concentrations was observed. Figure 1 summarizes the observed trough total and
unbound concentrations on days 3, 4, 7, and 10 and illustrates the accumulation of total
and unbound teicoplanin over time.
The proportions of patients with a trough total concentration at 48 h (trough48 h-total)
and at 72 h (trough72 h-total) of 20 mg/liter were 16.7% (5/30) and 37.9% (11/29),
respectively. The proportions of patients with a trough unbound concentration at 48 h
(trough48 h-unbound) and at 72 h (trough72 h-unbound) of 1.5 mg/liter were 26.7% (8/30)
and 37.9% (11/29), respectively. There was a moderate correlation between trough total
and unbound concentrations at 48 h (r  0.721, P  0.001) and at 72 h (r  0.692, P 
0.001) (Fig. 2). The FF of teicoplanin showed high interpatient variation, with FFs
ranging from 3.4 to 18.8%. Higher FFs were observed in patients with low serum
albumin concentrations (Fig. 3).
Factors associated with trough concentrations attained. All 30 patients were
included in analyses of the trough concentrations at 48 h. Twenty-nine patients were
included in analyses of the trough concentrations at 72 h, with one patient being
excluded due to a lack of a trough concentration measurement at this time. A CLCR of
1 ml/min was assumed for one patient on the basis of urine output of 10 ml on
this day.
Trough48 h-total. The only factors signiﬁcantly associated with the log trough48 h-total
were the estimated glomerular ﬁltration rate (eGFR), determined using the unadjusted
TABLE 1 Demographic and clinical details for the patients included in the studya
Characteristic Value
No. (%) of male patients 14 (46.7)
Median (IQR) age (yr) 64 (14)
Mean  SD:
TBW (kg) 69.1 15.8
IBW (kg) 56.7 10.1
Body mass index (kg/m2) 26.0 5.3
CLCR (ml/min)b 72 41
Median (IQR) serum albumin concn (g/liter)b 29 (4)
Mean  SD ﬂuid input (liters)b 2.8 1.1
No. (%) of patients with the following hematological
malignancy diagnosis:
Acute lymphoblastic leukemia 1 (3.3)
AML 7 (23.3)
Chronic lymphocytic leukemia 1 (3.3)
Hodgkin’s lymphoma 1 (3.3)
Non-Hodgkin’s lymphoma 13 (43.3)
Multiple myeloma 6 (20.0)
Myelodysplastic syndrome 1 (3.3)
No. (%) of patients who received a bone marrow transplant 7 (23.3)
Median (IQR) MASCCc risk index scored 16 (5)
Median (IQR) Charlson comorbidity indexe 6 (3)
Severe neutropeniaf 25 (83.3)
Mean  SD loading dose (mg/kg)g 9.5 1.9
Mean  SD daily maintenance dose (mg/kg) 10.0 1.8
Mean  SD duration of therapy (days) 9 4
aData are for 30 patients.
bValue on day 3 of teicoplanin therapy.
cMASCC, Multinational Association for Supportive Care in Cancer.
dSee reference 29.
eSee reference 30.
fSevere neutropenia was deﬁned as an absolute neutrophil count of 0.5  109/liter.
gAdministered for three doses at the start of teicoplanin therapy.
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four-variable modiﬁcation of diet in renal disease equation (MDRD) (R2  14.0%, P 
0.05) and the four-variable MDRD adjusted for body surface area (BSA) (MDRDa) (R2 
14.6%, P  0.05), with a negative relationship, and the Multinational Association for
Supportive Care in Cancer (MASCC) score (R2  17.2%, P  0.05), with a positive
relationship.
The best multiple-regression model including cumulative dose (in milligrams per
kilogram of body weight) was as follows: log trough48 h-total  1.0200  0.0110
cumulative dose  0.0019 MDRD result (R2  24.4%, P  0.05, variance inﬂation factor
[VIF]  1.00).
Trough72 h-total. All renal function measures were signiﬁcantly negatively associated
with the log trough72 h-total, including the measured CLCR (R2  33.5%, P  0.001), the
eGFR determined using MDRD (R2  25.5%, P  0.01) and MDRDa (R2  33.0%, P 
0.005), and the eCLCR determined using the Cockcroft-Gault equation (23) using total
body weight (TBW) (CG-TBW) (R2  24.3%, P  0.01) and the Cockcroft-Gault equation
using ideal body weight (IBW) calculated by the Devine equation (24) (CG-IBW) (R2 
19.0%, P  0.05). IBW showed a signiﬁcant negative association (R2  17.6%, P  0.05)
FIG 1 Trough total teicoplanin concentrations (left) and trough unbound teicoplanin concentrations (right) on days 3, 4, 7, and
10. Data are presented as the median, IQR, and range.
FIG 2 Relationship between trough total and trough unbound teicoplanin concentrations. The solid line is a least-squares ﬁt
to the data. Pearson correlation coefﬁcients were 0.722 (P  0.001, n  30) and 0.692 (P  0.001, n  29) for trough
concentrations at 48 h and 72 h, respectively.
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and the MASCC score showed a signiﬁcant positive association (R2  17.9%, P  0.05)
with the log trough72 h-total.
The best multiple-regression model including cumulative dose (in milligrams per
kilogram of body weight) was as follows: log trough72 h-total  1.1100  0.0025
cumulative dose  0.0021 CLCR  0.0134 MASCC score (R2  50.1%, P  0.005, VIF 
1.17).
According to this model, for a standard 70-kg patient with a CLCR of 70 ml/min and
a MASCC score of 16, the estimated loading regimen required to achieve a trough72 h-total
of 20 mg/liter is 900 mg (13 mg/kg) every 12 h for three doses and then a further dose
24 h later.
Trough48 h-unbound. IBW was the only factor signiﬁcantly associated with the log
trough48 h-unbound, with a negative relationship (R2  20.3%, P  0.05). No multiple-
regression models were considered acceptable.
Trough72 h-unbound. Simple regression showed that all renal function measures
were signiﬁcantly negatively associated with the log trough72 h-unbound, including the
measured CLCR (R2 41.9%, P 0.001), the eGFR determined using MDRD (R2 16.2%,
P  0.05) and MDRDa (R2  23.5%, P  0.01), and the eCLCR determined using CG-TBW
(R2 20.8%, P 0.05) and CG-IBW (R2 22.9%, P 0.01). IBW (R2 31.0%, P 0.005),
ﬂuid input (R2  22.3%, P  0.05), and albumin concentration (R2  16.3%, P  0.05)
were also signiﬁcantly negatively associated with the log trough72 h-unbound.
The best multiple-regression model including cumulative dose (in milligrams per
kilogram of body weight) was as follows: log trough72 h-unbound  0.1810  0.0046
cumulative dose  0.0033 CLCR (R2  43.8%, P  0.005, VIF  1.16). According to this
model, for a standard 70-kg patient with a CLCR of 70 ml/min, the estimated loading
regimen required to achieve a trough72 h-unbound of 1.5 mg/liter is 900 mg (13 mg/kg)
every 12 h for three doses and then a further dose 24 h later.
Comparison of renal function estimation equations. The performance character-
istics of the renal function estimation equations relative to the measured CLCR are
shown in Table 2 and Fig. S1 in the supplemental material. MDRDa and MDRD had the
lowest bias. CG-TBW and the Jelliffe equation (JEL) (25) had the highest precision.
Accuracy, in terms of the highest percentage of estimates within 30% of the measured
CLCR, was the highest for JEL and CG-TBW. Accuracy, in terms of the smallest root mean
FIG 3 Relationship between the percentage of unbound teicoplanin and the serum albumin concen-
tration. The trough unbound concentrations determined on days 3, 4, 7, and 10 are included in the plot
(n  95). The curved line is the quadratic least-squares ﬁt to the data. The Pearson correlation coefﬁcient
was 0.599 (P  0.001).
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square error, was the highest for the Chronic Kidney Disease Epidemiology Collabora-
tion equation (CKD-EPI) and CG-TBW. Overall, CG-TBW, JEL, and CKD-EPI performed
comparatively well for estimating the measured CLCR. A comparison of the model-
predicted versus the observed trough72 h-total in study patients, using the measured
CLCR and using the estimated CLCR (eCLCR), calculated by CG-TBW, as a substitute for
the measured CLCR, is provided in Fig. 4.
Response to teicoplanin therapy. Of the 30 febrile episodes, 7 were deemed
evaluable for assessment of the response to teicoplanin, and all were methicillin-
resistant CoNS CLABSIs. Of these, there were four successful outcomes and three
failures. The median time to failure was 8 days (range, 3 to 14 days). The causes of
failure were the persistence of fever in two cases and the persistence of both fever and
the pathogen in one case. Central lines were retained in all successful cases but not in
the three failures. Teicoplanin MICs were available in six cases (three successful cases
and three failures), and all were below the European Committee on Antimicrobial
Susceptibility Testing breakpoint for susceptibility of CoNS of 4 mg/liter (Table 3) (26).
There was no signiﬁcant difference in clinical or demographic factors between
successful and failed cases. The mean  standard deviation (SD) trough total and
unbound concentrations and trough total concentration/MIC and trough unbound
concentration/MIC ratios were higher in successful cases than in failed cases, although
the differences were not statistically signiﬁcant (Table 3).
TABLE 2 Comparison of the performance of renal function estimation equations relative to measured CLCR in the study populationa
Equation (CLCR units)
Median
differenceb (bias)
IQR for differenceb
(precision)
% of estimates within 30%
of measured CLCR
(accuracy)
% root mean square
error (accuracy)
CG-TBW (ml/min) 3.0 29.5 63.3 29.5
CG-IBW (ml/min) 8.5 44.3 53.3 38.9
MDRD (ml/min/1.73 m2) 2.0 48.8 53.3 39.2
MDRDa (ml/min) 1.0 44.0 53.3 36.6
CKD-EPI (ml/min/1.73 m2) 3.0 32.0 60.0 29.1
JEL (ml/min/1.73 m2) 2.5 30.3 66.7 32.0
aData are for 30 patients. CLCR, creatinine clearance; CG-TBW, Cockcroft-Gault equation (23) using total body weight; CG-IBW, Cockcroft-Gault equation using ideal
body weight calculated by the Devine equation (24); MDRD, unadjusted four-variable modiﬁcation of diet in renal disease equation (32); MDRDa, four-variable
modiﬁcation of diet in renal disease equation adjusted to the body surface area of the individual patient calculated by the Mosteller equation (31); CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration equation (33); JEL, Jelliffe equation (25).
bDifference refers to the estimated CLCR value minus the measured CLCR value.
FIG 4 Comparison of model-predicted versus observed trough total teicoplanin concentrations in study patients using
measured creatinine clearance (measured CLCR model) and using estimated creatinine clearance calculated by the Cockcroft-
Gault equation (23) with total body weight (estimated CLCR model) as a substitute for the measured creatinine clearance. The
diagonal lines in each plot represent lines of x equal to y.
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Adverse events. Overall, teicoplanin was well tolerated. Four patients developed a
skin rash (13.3%), but in all cases other medications with a known potential to cause
skin rash were used concurrently. A severe hypersensitivity reaction developed in one
patient within minutes after the intravenous infusion commenced, even though the
patient had been treated with teicoplanin on a previous admission without conse-
quence.
Nephrotoxicity was observed in ﬁve patients (16.7%). Of these, four were cotreated
with other potentially nephrotoxic drugs, and most often this was an aminoglycoside.
In the remaining case, the onset of acute kidney injury ensued 3 days before teicoplanin
was commenced. There was no signiﬁcant difference in the highest trough total
concentration between cases with evidence of nephrotoxicity (median, 30.2 mg/liter;
interquartile ratio [IQR], 15.6 mg/liter; range, 13.9 to 37.5 mg/liter; n 5) and cases with
no evidence of nephrotoxicity (median, 29.8 mg/liter; IQR, 14.3 mg/liter; range, 16.7 to
74.9 mg/liter; n  25) (P  1.000). There was no signiﬁcant difference in the duration
of therapy between cases with evidence of nephrotoxicity (mean, 8 days; SD, 6 days;
range, 3 to 14 days; n  5) and cases with no evidence of nephrotoxicity (mean, 10
days; SD, 4 days; range, 3 to 20 days; n  25) (P  0.565). There was no evidence of
hepatotoxicity in the study cohort.
DISCUSSION
The ﬁndings of this prospective study provide further evidence that higher loading
doses of teicoplanin are needed in patients with hematological malignancy. For an
TABLE 3 Comparison of successful versus failed teicoplanin treatments for cases of CoNS
CLABSIa
Characteristic
Value(s) for patients who had
treatment:
P valuebSuccess (n  4) Failure (n  3)
No. (%) of male patients 1 (25.0) 2 (66.7) 0.486
Mean  SD age (yr) 57 27 61 12 0.796
Mean  SD TBW (kg) 54.8 8.9 76.4 20.5 0.230
Mean  SD CLCR (ml/min)c 50 29 75 13 0.195
Median (IQR) serum albumin concn (g/liter)c 30 (5) 32 (13) 0.629
Severe neutropeniad 3 (75.0) 2 (66.7) 1.000
Median (IQR) MASCCe risk index scoref 18 (2) 16 (8) 0.057
Charlson comorbidity indexg 6 3 6 2 0.731
Mean loading dose (mg/kg) 11.2 2.0 8.7 0.9 0.093
Mean daily maintenance dose (mg/kg) 11.2 2.0 10.9 1.4 0.830
Combination therapyh 3 (75.0) 3 (100.0) 1.000
Mean  SD (range):
Teicoplanin MIC (mg/liter)i 1.4 1.4 (0.4–3.0) 1.5 0.5 (1.0–2.0) 0.900
Trough48 h-total (mg/liter) 18.6 12.3 12.6 7.6 0.471
Trough48 h-unbound (mg/liter) 1.6 1.2 1.3 1.0 0.711
Trough72 h-total (mg/liter) 22.8 15.2 16.4 5.5 0.495
Trough72 h-unbound (mg/liter) 1.75 1.25 1.5 0.9 0.770
Trough48 h-total/MICi 30.9 24.4 10.3 8.2 0.297
Trough48 h-unbound/MICi 2.8 2.2 1.1 1.2 0.321
Trough72 h-total/MICi 38.1 29.9 12.7 7.7 0.289
Trough unbound concn at 72 h/MICi 3.4 2.7 1.2 1.1 0.325
aData are for seven patients.
bP values were determined by Fisher’s exact test for categorical covariates or an unpaired Student’s t test or
the Mann-Whitney U test for continuous covariates.
cValues on day 3 of teicoplanin therapy.
dSevere neutropenia was deﬁned as an absolute neutrophil count of 0.5  109 liter1.
eMASCC, Multinational Association for Supportive Care in Cancer.
fSee reference 29.
gSee reference 30.
hCombination therapy was other antibiotics administered concurrently with teicoplanin: piperacillin-
tazobactam (n  4 patients), gentamicin (n  3 patients), meropenem (n  3 patients), ciproﬂoxacin (n  2
patients), and amikacin (n  1 patient).
iResult based on 3 successful treatments and 3 failures.
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average hematological malignancy patient, the regression models developed suggest
that sequential loading doses of at least 12 mg/kg would be needed to achieve early
adequate exposure. Loading doses of 12 mg/kg every 12 h for 3 to 5 doses are currently
recommended for bone and joint infections to achieve trough concentrations of 20
mg/liter (14). Adoption of these dosing recommendations for hematological malig-
nancy patients may be an appropriate consideration. After adequate loading, mainte-
nance dosing should be guided by therapeutic drug monitoring (TDM).
Consistent with the ﬁndings of studies with other patient groups (13, 19–21), the FFs
of teicoplanin in the study patients were highly variable, with higher FFs being
observed in patients with low serum albumin concentrations. In recent years, the
importance of TDM of unbound teicoplanin concentrations has been highlighted for
critically ill and chronically ill patients (13, 20, 21). Given the observed variability in
protein binding and the lack of a strong correlation between trough total and unbound
concentrations, TDM of unbound teicoplanin concentrations may prove useful in the
future.
The regression analyses showed that renal function is an important consideration for
appropriate initial teicoplanin dosing, which is in keeping with the ﬁndings of recently
published studies (16, 27, 28). Although the impact of renal function on trough
concentrations was stronger at 72 h than at 48 h, the results suggest that in patients
with enhanced renal function, achieving target trough concentrations may be difﬁcult
unless very high loading doses, such as doses of 	20 mg/kg, are used. The measured
CLCR had a stronger association with the trough concentrations than estimated values
calculated using renal function estimation equations. Should measured CLCR data not
be available, given the experience with the use of eCLCR in clinical practice and the
results of the comparison of renal function estimation equations, the eCLCR calculated
using CG-TBW could be proposed to be a surrogate for the measured CLCR in this
patient group. The difference between signiﬁcant factors associated with trough
unbound concentrations at 48 h and those associated with trough unbound concen-
trations at 72 h is difﬁcult to explain but may reﬂect changes in pathophysiology and/or
teicoplanin distribution.
In our previous retrospective study, a diagnosis of AML showed a signiﬁcant
negative association with trough total concentrations (16), although this was not found
to be the case in the current study. This may have been due to the smaller sample size
and the lower number of AML patients in the current study (n  7) than in the
retrospective study (n  20). We postulated that AML patients may have an underlying
pathophysiology different from that of patients with other types of hematological
malignancy, including higher ﬂuid loads, higher levels of inﬂammation, and/or a greater
severity of illness. Indeed, in the current study, the ﬂuid input and MASCC score were
signiﬁcantly associated with trough concentrations. The MASCC score is a composite
score used to identify the risk of complications in febrile neutropenic cancer patients,
with lower scores indicating a higher risk of complications (29). It is possible that lower
MASCC scores reﬂect an altered pathophysiology and/or the use of supportive treat-
ments, such as aggressive ﬂuid therapy, in sicker patients, resulting in the enhanced
disposition of teicoplanin.
Demonstration of a relationship between teicoplanin concentrations and clinical
outcome would have been useful to guide practice in this patient group. However,
establishment of the efﬁcacy of an individual antibacterial agent in neutropenic pa-
tients is difﬁcult because antibacterial treatment is often prescribed empirically and
these patients are frequently on several antibacterial agents concurrently. Such was the
case in the current study, with only seven patients being evaluable for assessment of
teicoplanin efﬁcacy, and therefore, no further insight into the appropriate trough
concentration target for teicoplanin in hematological malignancy patients was gained.
Nevertheless, the mean  SD trough48 h-total of 18.6  12.3 mg/liter and the mean 
SD trough72 h-total of 22.8  15.2 mg/liter, observed in successful cases in the current
study, were consistent with the ﬁndings of previous studies suggesting a target trough
concentration of 20 mg/liter (15, 16). While our data do not allow determination of the
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MIC value that this trough concentration target relates to, it might be prudent to
consider higher levels of exposure for patients with infections with pathogens with
MICs of 	1 mg/liter.
Of course, the beneﬁts of using higher teicoplanin doses to produce higher trough
concentrations must be balanced against the potential risk of increased toxicity. In the
current study, with trough concentrations ranging from 4.1 to 70.5 mg/liter between
days 3 and 10, teicoplanin was well tolerated. Apart from the severe hypersensitivity
reaction in one patient, none of the adverse events observed could deﬁnitely be
attributed to teicoplanin. Furthermore, no relationship between trough concentrations
and the incidence of adverse events was observed.
This study had several limitations. First, the study was conducted in a single center
and the sample size was small. Second, no conclusions about the relationship between
drug exposure and clinical outcomes could be made because there were too few
microbiologically documented Gram-positive bacterial infections. Third, the current
study does not allow statements to be made about the relationship between trough
levels and toxicity outside the range of trough levels observed in this study. Fourth,
therapeutic targets for teicoplanin are not well deﬁned, and therefore, the dosing
estimations may be different should new targets be determined in the future.
In conclusion, to achieve target trough concentrations early in therapy, loading
doses of teicoplanin higher than those in current use appear to be necessary in patients
with hematological malignancy. Renal function is an important consideration for
appropriate initial dosing of teicoplanin. The serum albumin concentration has a
signiﬁcant effect on unbound teicoplanin concentrations. The high variability in protein
binding supports the contention for TDM of unbound concentrations.
MATERIALS AND METHODS
Setting. This single-center, prospective study was conducted at Tallaght Hospital, Dublin, Ireland.
Ethical approval was obtained from the Tallaght Hospital/St. James’s Hospital Joint Research Ethics
Committee (REC reference 2013/12/01). The study protocol was authorized by the Health Products
Regulatory Authority (clinical trial number CT 900/545/1), and the trial was registered with the European
Clinical Trials Database (EudraCT registration number 2013-004535-72). The study was conducted
following the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all
patients.
Study population. Inclusion criteria were an age of 18 years, a diagnosis of a hematological
malignancy, treatment with teicoplanin for 	48 h, the presence of an intravascular catheter, and
provision of written informed consent to participate in the study. Patients who were receiving renal
replacement therapy, were admitted to the Intensive Care Unit, or were incapable of comprehending the
nature and scope of the trial were excluded from enrollment. Patients were also excluded if blood
sampling personnel, an analyst, or processing equipment was not available.
Dosing regimen. Teicoplanin (Targocid; Sanoﬁ, Dublin, Ireland) was administered intravenously by
slow bolus injection. The hospital dosage regimen was 600 mg (or 800 mg, if the patient’s weight
was 	80 kg) every 12 h for three loading doses, followed by 600 mg (or 800 mg, if the patient’s weight
was 	80 kg) once daily. However, prescribed dosing regimens were at the discretion of the treating
physicians, and the hospital dosage regimen was not always followed.
Blood sampling, handling, and storage and concentration measurement. Samples for trough
concentration determination (samples obtained at 24 h postdosing) were taken on days 3 (48 h), 4 (72
h), and 7 and 10 (when applicable). Samples were immediately refrigerated and within 6 h were
centrifuged at 3,000 rpm for 10 min. The supernatant was stored at 80°C until analysis. Total and
unbound teicoplanin concentrations were determined using high-performance liquid chromatography
as described by Roberts et al. (13).
Determination of CLCR. Urine was collected over a 24-h period on day 3. The volume of urine was
measured, and a 1-ml aliquot was stored at 80°C until analysis. The urine creatinine concentration was
determined locally using an enzymatic method performed on a Roche/Hitachi Cobas C702 AutoAnalyzer
system (Roche Diagnostics GmbH, Mannheim, Germany). The urine volume, the serum creatinine
concentration (Scr) on the day of urine collection, and the urine creatinine concentration were used to
calculate the measured CLCR.
MIC testing. The identiﬁcation of isolates from study patients was determined locally by broth
microdilution using a Vitek2 system (bioMérieux UK Ltd., Basingstoke, UK) per routine care. The
teicoplanin MICs of Gram-positive isolates from cultures of blood taken from the study patients were
determined locally with MIC test strips (Lioﬁlchem, Italy).
Additional data. Additional clinical and demographic data, including age, body weight, height,
serum albumin concentration, blood counts, 24-h ﬂuid balance on day 3, and measures of illness severity,
including the Multinational Association for Supportive Care in Cancer (MASCC) risk index score (29) and
the Charlson comorbidity index (30), were collected. If a laboratory value was missing on a particular day,
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the value on the next closest day to that day was used, provided it was obtained within 2 days of the
missing value.
Ideal body weight (IBW) was estimated using the Devine equation (24). Body surface area (BSA) was
estimated using the Mosteller equation (31). The estimated CLCR (eCLCR) was calculated using the
Cockcroft-Gault equation with total body weight (TBW) (CG-TBW) and IBW (CG-IBW) (23) and the Jelliffe
equation (JEL) (25). The estimated glomerular ﬁltration rate (eGFR) was calculated using the unadjusted
four-variable modiﬁcation of diet in renal disease equation (MDRD) and MDRD adjusted for BSA (MDRDa)
(32) and the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) (33).
Factors associated with trough concentrations attained. The relationship between patient factors
and the trough total concentrations at 48 h (trough48 h-total) and 72 h (trough72 h-total) and trough
unbound concentrations at 48 h (trough48 h-unbound) and 72 h (trough72 h-unbound) attained was assessed.
Log trough concentrations were used for the dependent variable, as the data were positively skewed.
The independent variables tested included age, hematological malignancy diagnosis, receipt of a bone
marrow transplant, sickness severity scores, measured CLCR (day 3 only), eCLCR and eGFR, serum albumin
concentration, ﬂuid balance, and ﬂuid input.
Stepwise incorporation of covariates was conducted for multivariate model development, with the
cumulative dose (in milligrams per kilogram of body weight) being included in all models. Covariates that
did not contribute to or reduced the ﬁt of the model were removed sequentially, and only signiﬁcant
covariates were retained. The target trough total concentration was 20 mg/liter, and the target trough
unbound concentration was 1.5 mg/liter, assuming 92.5% protein binding. These targets were based on
those suggested from previously published studies (13, 15, 16).
Comparison of renal function estimation equations. The performances of renal function estima-
tion equations for estimating the measured CLCR were compared. The CG-TBW, CG-IBW, and MDRDa
estimates were compared with the measured CLCR (in milliliters per minute). The CLCR estimates obtained
by MDRD, CKD-EPI, and JEL were compared with the measured CLCR (in milliliters per minute per 1.73
m2). Bias was assessed as the median difference, with positive values indicating overestimation of the
measured CLCR. Precision was assessed as the IQR for the differences. Accuracy was assessed as the root
mean square error and the percentage of estimates within 30% of the measured CLCR (33).
Response to teicoplanin therapy. Assessment of the response to teicoplanin therapy was con-
ducted using the same methods and deﬁnitions previously described by Byrne et al. (16).
Nephrotoxicity and hepatotoxicity. Nephrotoxicity was assessed by comparing the Scr on the ﬁrst
and last days of teicoplanin therapy. Nephrotoxicity was deﬁned as an increase in the Scr of 	0.5 mg/dl
or 50% (34).
Hepatotoxicity was assessed by comparing the serum alanine transaminase (ALT) level on the ﬁrst
and last days of teicoplanin therapy and was deﬁned as an increase in the ALT concentration of	3 times
the upper limit of normal or 	3 times the baseline level if the level was abnormal on day 1 (34).
Statistical analyses. All statistical analyses were conducted using IBM SPSS Statistics for Windows (v.
22; IBM Corp., Armonk, NY) or Minitab 16 (Minitab Ltd., Coventry, UK) statistical software. Data were
described as the mean  SD or the median (IQR) for continuous variables and as the number (percent)
of patients for categorical variables. Either an unpaired Student’s t test or the nonparametric Mann-
Whitney U test was used to compare groups for continuous variables. Fisher’s exact test was used to
compare groups for categorical covariates. The correlation between continuous variables was evaluated
using the Pearson correlation coefﬁcient (r). Simple and multiple-regression analyses were used to assess
the relationship between patient factors and trough concentrations. Statistical signiﬁcance was deﬁned
as a P value of 0.05.
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